Companies/US/SLN

SILENCE THERAPEUTICS PLC

Last · NASDAQ$8.98+0.11 (+1.24%)close · yahoo · 15h ago
Vol 1.23M ≈ 11.07M
Market cap$558.14M62.2M sh
P/E · TTM-7.0fwd -23.6 · eps -1.29 · loss
Beta1.45vs S&P 500
Div yield0.00%annual · TTM
52w range
$4.19$17.58
Volume1.2Msession

Issuer

Legal nameSILENCE THERAPEUTICS PLC
HQUnited States (US)
ListingUS SLN
ISINUS82686Q1013
SectorHealthcare
IndustryDrugs (Pharmaceutical)
SIC2834
CurrencyUSD
Entity registrysec:0001479615
CIK0001479615
Employees88
AddressSilence Therapeutics Plc 12 Hammersmith Grove W6 7AP, London +44 20 3457 6900
Headline financial metrics
Revenue$43.3M
Operating income$-63.3M
Net income$-45.3M
Free cash flow$-67.9M
Operating margin-146.4%
Net margin-104.7%
Return on equity-33.8%
Period2024
Loading chart…

OpenFilings analyst

Our analyst

10-K · 2026-03-05

From latest 10-K · 2026-03-05

  • Sbc Revenue High
  • Operating Cf Burn
  • Net Margin Sharply Negative
  • Cash Conversion Weak
  • Cash Runway Low
  • Accumulated Deficit High
  • Rd Intensity High

Red flags

  • Sbc Revenue High — SBC/Revenue 1444.4%
  • Operating Cf Burn — Negative operating cash flow
  • Net Margin Sharply Negative — Net margin -15851.9%
  • Cash Conversion Weak — Cash conversion (CFO/Rev) -11139.7%
  • Cash Runway Low — Cash runway ~0.2 years
  • Accumulated Deficit High — Accumulated deficit / equity 903%
  • Rd Intensity High — R&D/Revenue 12120.4%

Upcoming earnings

1 event
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.09
Est. revenue
20,670

Earnings transcripts

10 recent

Documents

FormReporting forFiledFlags
2026-08-102026-08-130